China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a revenue increase to RMB 1.72 billion and a net profit of RMB 425 million. Despite a decrease in cash and cash equivalents, the company maintained strong total assets and owner’s equity, indicating stable financial health. Stakeholders are advised to exercise caution as these figures are unaudited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company holds significant equity interests in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange, known for its production of traditional Chinese medicine products.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.5B
For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.